Comparison of ticagrelor, the first reversible oral P2Y.sub.12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

MLA

“Comparison of Ticagrelor, the First Reversible Oral P2Y.Sub.12 Receptor Antagonist, with Clopidogrel in Patients with Acute Coronary Syndromes: Rationale, Design, and Baseline Characteristics of the PLATelet Inhibition and Patient Outcomes (PLATO) Trial.” American Heart Journal, vol. 157, no. 4, Apr. 2009, p. 599. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.196758007&authtype=sso&custid=ns315887.

APA

Comparison of ticagrelor, the first reversible oral P2Y.sub.12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. (2009). American Heart Journal, 157(4), 599.

Chicago

“Comparison of Ticagrelor, the First Reversible Oral P2Y.Sub.12 Receptor Antagonist, with Clopidogrel in Patients with Acute Coronary Syndromes: Rationale, Design, and Baseline Characteristics of the PLATelet Inhibition and Patient Outcomes (PLATO) Trial.” 2009. American Heart Journal 157 (4): 599. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.196758007&authtype=sso&custid=ns315887.